Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx, Alcyomics Win $1M for Inflammatory Response Marker Project

NEW YORK (GenomeWeb News) – The Belgian diagnostics developer VolitionRx and the UK-based preclinical drug safety testing firm Alcyomics will use a €779,493 ($1 million) grant to develop biomarkers for indicating inflammatory response, the companies said today.

Under the initiative, the partners will seek to identify novel epigenetic biomarkers for early inflammation and rejection responses linked to graft-versus host disease, which can cause complications in hematopoietic stem cell transplantation.

The two-year project is funded by Eureka, a 41-member European network that seeks to spur the growth of Europe-based technology companies, through its Eurostars Programme, which is focused on supporting small and medium-sized enterprises.

VolitionRx will develop new applications for its Nucleosomics biomarker technology and new biomarkers for immune response. It will receive €420,000 for its contribution to the project. The Nucleosomics technology is used to identify and measure nucleosomes in the bloodstream, which indicate that cancer is present.

The partners also will use Alcyomics' Skimune model, under which it offers a line of assays for testing and measuring immunogenicity, hypersensitivity, allerginicity, efficacy, and potency.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.